Sun Pharma settles US patent litigation with Actavis over skin care drug

Ranbaxy, Cipher and Galephar enter into a non-exclusive license agreement with Actavis

Reghu Balakrishnan
Updated5 Oct 2015, 08:01 PM IST
The settlement is subject to review by the US Federal Trade Commission and the US department of justice, Sun Pharma said. Photo: Bloomberg<br />
The settlement is subject to review by the US Federal Trade Commission and the US department of justice, Sun Pharma said. Photo: Bloomberg

Mumbai: Ranbaxy Pharmaceuticals Inc., a unit of Sun Pharmaceutical Industries Ltd, has settled a patent litigation with Actavis over the generic version of Absorica, a drug used to treat acne.

Ranbaxy, along with its partners, Cipher Pharmaceuticals Inc. and Galephar Pharmaceutical Research, Inc. have entered into a settlement with Actavis that dismisses the lawsuit relating to Actavis’s abbreviated new drug application (ANDA) for a generic version of Absorica (isotretinoin capsules), Sun Pharma said.

Absorica is used to treat severe recalcitrant nodular acne, a skin disease, in patients 12 years of age and older.

As part of the agreement, Ranbaxy, Cipher and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may start selling its generic version of Absorica in the US on 27 December 2020 (nine months before the expiration of the patents in September 2021) or earlier under certain circumstances, it said.

In 2014, Ranbaxy had introduced Absorica 25 mg and 35 mg capsules in the US after the product was licensed from Cipher Pharmaceuticals, Inc.

The settlement is subject to review by the US Federal Trade Commission and the US department of justice, Sun Pharma said.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.MoreLess
First Published:5 Oct 2015, 08:01 PM IST
HomeCompaniesSun Pharma settles US patent litigation with Actavis over skin care drug

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Tata Steel

    157.75
    03:43 PM | 19 JUL 2024
    -8.6 (-5.17%)

    Tata Power

    414.15
    03:59 PM | 19 JUL 2024
    -15.85 (-3.69%)

    Bharat Electronics

    306.30
    03:45 PM | 19 JUL 2024
    -7.2 (-2.3%)

    Zee Entertainment Enterprises

    137.55
    03:57 PM | 19 JUL 2024
    -4.9 (-3.44%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Tata Teleservices Maharashtra

    102.11
    03:59 PM | 19 JUL 2024
    4.68 (4.8%)

    Rail Vikas Nigam

    614.00
    03:59 PM | 19 JUL 2024
    27.65 (4.72%)

    Jubilant Pharmova

    752.25
    03:43 PM | 19 JUL 2024
    25.3 (3.48%)

    One 97 Communications

    458.70
    03:55 PM | 19 JUL 2024
    13.65 (3.07%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      75,217.00292.00
      Chennai
      75,657.001,099.00
      Delhi
      74,485.00-659.00
      Kolkata
      74,485.00-73.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.86/L0.00
      Chennai
      100.75/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.72/L0.00
      OPEN IN APP
      HomeMarketsCibilPremiumBudget